Abeona Therapeutics Inc.

NasdaqCM:ABEO Rapport sur les actions

Capitalisation boursière : US$310.5m

Abeona Therapeutics Croissance future

Future contrôle des critères 5/6

Abeona Therapeutics devrait augmenter ses bénéfices et ses revenus de 70.1% et de 42.2% par an respectivement, tandis que le BPA devrait croître de croître de 70.7% par an.

Informations clés

70.1%

Taux de croissance des bénéfices

70.69%

Taux de croissance du BPA

Biotechs croissance des bénéfices29.0%
Taux de croissance des recettes42.2%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Good

Dernière mise à jour24 Aug 2026

Mises à jour récentes de la croissance future

Recent updates

Seeking Alpha • Nov 10

Abeona Therapeutics: ZEVASKYN Data Key In Gauging Momentum - Why I Hold

Summary Abeona Therapeutics (ABEO) is at a critical juncture, trading near 52-week lows ahead of its first ZEVASKYN revenue update in Q3. ZEVASKYN, a one-time gene therapy for severe skin disorder, faces execution risks but offers potential market share versus established competitor Vyjuvek. ABEO maintains a strong cash position with over two years of runway, but profitability depends on scaling patient treatments and overcoming manufacturing and regulatory hurdles. Despite a discounted valuation and strong analyst ratings, I rate ABEO as HOLD until Q3 results clarify ZEVASKYN's commercial traction and patient conversion rates. Read the full article on Seeking Alpha
Article d’analyse • Jan 15

Health Check: How Prudently Does Abeona Therapeutics (NASDAQ:ABEO) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Article d’analyse • Sep 23

Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Article d’analyse • May 01

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Article d’analyse • Jan 04

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Article d’analyse • Aug 16

Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse • Mar 31

Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 19

Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value

Summary Results from the pivotal VITAL study, using EB-101 for the treatment of patients with RDEB are expected to be released before the end of 2022. Should EB-101 be approved by FDA for RDEB, it would give company a Priority Review Voucher, which could be sold for around $100 million or more to another pharmaceutical company. ABO-102, which is being developed to treat patients with Sanfilippo syndrome type A has been offloaded to Ultragenyx Pharmaceutical for advancement. Abeona has $26 million in cash as of June 30, 2022. It believes enough cash to fund operations until Q2 of 2023, but will likely have to raise cash before or after data from this late-stage study. Abeona Therapeutics (ABEO) is a great speculative biotech play to look into. That's because it is gearing up to report results from its phase 3 pivotal study known as VITAL. This late-stage study is using its cell therapy known as EB-101 for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB). Results from this trial are expected any day now before the end of 2022, therefore, this provides traders/investors with a huge catalyst to look forward to. Abeona wants to focus on this program for its pipeline, therefore, it chose to offload ABO-102 (now UX111) for Sanfilippo syndrome type A ((MPS IIIA)) to Ultragenyx Pharmaceutical (RARE). That is, Ultragenyx will be responsible for taking over this program and moving it forward in the clinic. In return, Abeona will be receiving tiered royalties and commercial milestone payments should this drug ultimately be approved by regulators. With proof of concept established with EB-101 in a prior study, plus year-end 2022 data readout of EB-101 for RDEB, these are the reasons why I believe it is a great speculative biotech play to look into. EB-101 Could Possibly Provide A Great Long-Term Durable Treatment Option For RDEB Patients The main program in the pipeline is EB-101, which is being developed for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a terrible skin condition by which there is lack of collagen protein in the skin. It is a condition by which wounds are large and blisters tend to form. Patients with RDEB suffer greatly because of pain and complications which occur because of it. That's not the only problem to consider though for this patient population. The average life expectancy of someone who has it is 50 years of age. There are not currently any cures available for these patients, but there are treatments that attempt to control symptoms and pain. The main problem is that a mutation in the COL7A1 gene doesn't allow the formation of Type VII collagen, which is necessary for the skin to be healthy. EB-101 is a cell therapy which is being developed to provide functional collagen VII to the patient's own cells. The therapy is autologous, that is, cells are extracted from the patient and then transduced with the correct collagen gene necessary for proper formation. The final outcome is a fully formed sheet which is 5 to 7 cell layers thick. EB-101 is eventually applied to the wound in surgery which helps the patient to restore their functionality of COL7A1 gene encoding provided by the cells. In turn, EB-101 holds the potential to heal and provide pain relief for the patient. Even better, it provides a "one and done" scenario whereby it may be possible to avoid daily wound care. Abeona expects that EB-101 could produce estimated cumulative revenues of $1.5 billion over the products life cycle. As I highlighted in the beginning Abeona Therapeutics is currently running its phase 3 VITAL study, which is using EB-101 for the treatment of patients with RDEB. It has been reported that the final patient completed their 6-month follow-up visit for this late-stage trial on October 4, 2022. This means within the next 3 to 4 weeks, investors should get an idea on whether or not this cell therapy succeeds in meeting the co-primary endpoints for this study. This means before the end of 2022, there will be a data readout from this VITAL study which could possibly boost shareholder value. Of course, both co-primary endpoints must be met for this to happen. Developing a treatment for large chronic wounds is not easy, as such, Abeona and the FDA came to an agreement on what the co-primary endpoints need to be in order for EB-101 to be approved for RDEB. The two co-primary endpoints necessary for regulatory approval are: Proportion of chronic wounds with ≥50% healing from baseline at week 24 (Those treated with EB-101 versus those not treated at all with EB-101) Pain reduction at dressing changes assesses by a mean difference in scores using the Wong-Baker FACES scale at week 24 (Treated EB-101 versus untreated EB-101)
Seeking Alpha • Oct 04

Abeona Therapeutics stock continues recent strong run, shares rise ~10%

Shares of Abeona Therapeutics (NASDAQ:ABEO) gained 10.4% to $3.62 in Tuesday mid-day trading, extending a recent strong run which has seen the stock post gains in four of its last five sessions. The stock rose 7.9% yesterday after Cantor Fitzgerald listed the development-stage biotech among four companies in whose planned phase 3 readout it had a "high conviction". The rebound in ABEO shares come after the stock posted a seven-day losing streak towards the end of last month. The company earlier in the day said the last patient had completed their six-month follow-up visit in its phase 3 study of its cell therapy EB-101 for the treatment of recessive dystrophic epidermolysis bullosa, the most severe form of a condition that causes fragile, blistering skin. ABEO plans to report results from the study within the next month. The study, called VIITAL, is expected to serve as a basis for the company's planned approval submission to the U.S. FDA for EB-101, the company said in a statement.
Seeking Alpha • Aug 11

Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M

Abeona Therapeutics press release (NASDAQ:ABEO): Q2 GAAP EPS of -$2.08. Revenue of $1M. Cash, cash equivalents, restricted cash and short-term investments totaled $26.0 million as of June 30, 2022.  Shares +1.68% PM.
Seeking Alpha • Jul 20

Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement

Abeona Therapeutics (NASDAQ:ABEO) received Nasdaq notification informing it has regained compliance with the minimum bid price requirement. The requirement was met on July 18, 2022.

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:ABEO - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202818028N/A965
12/31/2027119-9N/A307
12/31/202654-55N/A-387
6/30/202626-63-82-76N/A
3/31/20261566-85-78N/A
12/31/2025671-84-76N/A
9/30/2025082-82-75N/A
6/30/2025057-71-66N/A
3/31/2025N/A-44-63-60N/A
12/31/2024N/A-64-58-56N/A
9/30/2024N/A-71-51-49N/A
6/30/2024N/A-53-44-42N/A
3/31/20244-77-41-40N/A
12/31/20234-54-37-37N/A
9/30/20234-45-42-42N/A
6/30/20234-39-43-43N/A
3/31/20231-31-42-42N/A
12/31/20221-43-44-43N/A
9/30/20224-83-63-60N/A
6/30/20224-84-67-63N/A
3/31/20223-91-70-66N/A
12/31/20213-85-70-66N/A
9/30/20213-54-38-37N/A
6/30/202110-54-38-37N/A
3/31/202110-52-37-35N/A
12/31/202010-84-36-35N/A
9/30/20207-85-49-48N/A
6/30/2020N/A-95-57-55N/A
3/31/2020N/A-106N/A-61N/A
12/31/2019N/A-76N/A-63N/A
9/30/20190-77N/A-66N/A
6/30/20192-76N/A-56N/A
3/31/20192-65N/A-50N/A
12/31/20183-57N/A-39N/A
9/30/20183-48N/A-27N/A
6/30/20181-37N/A-25N/A
3/31/20181-33N/A-21N/A
12/31/20171-27N/A-23N/A
9/30/20171-26N/A-21N/A
6/30/20171-23N/A-18N/A
3/31/20171-22N/A-16N/A
12/31/20161-22N/A-13N/A
9/30/20161-17N/A-12N/A
6/30/20161-21N/A-11N/A
3/31/20161-18N/A-10N/A
12/31/20151-15N/A-10N/A
9/30/20151-25N/A-9N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ABEO devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 3.7% ).

Bénéfices vs marché: ABEO devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: ABEO devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ABEO ( 42.2% par an) devrait croître plus rapidement que le marché US ( 13.4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ABEO ( 42.2% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ABEO devrait être élevé dans 3 ans

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/09/15 00:21
Cours de l'action en fin de journée2026/09/15 00:00
Les revenus2026/06/30
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Abeona Therapeutics Inc. est couverte par 18 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
James MolloyAlliance Global Partners
George ZavoicoB. Riley Securities, Inc.
Kristen KluskaCantor Fitzgerald & Co.